Matias Aduriz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matias Aduriz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Moura de Oliveira
Universidade de São Paulo, Brazil
1 shared publication - Celina Guadalupe Vega
Instituto Nacional de Tecnologia Agropecuaria, Argentina
1 shared publication - Joana Rocha da Silveira Barreto de Aguiar
Universidade de São Paulo, Brazil
1 shared publication María Barrandeguy
1 shared publication- Paulo Eduardo Brandão
Universidade de São Paulo
1 shared publication - Samuel Miño
National University of Misiones
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 67, e63
Nanobodies as antivirals against rabies in experimentally infected mice
Despite its 100% lethality and approximately 59,000 human deaths every year, rabies still lacks an effective treatment. Numerous trials have aimed to impair the life cycle of Lyssavirus rabies (RABV), the primary worldwide lyssavirus causing rabies, but with limited success. Treatments targeting host factors and attempting to mitigate the damage caused by RABV have also been unsatisfactory. This article describes the effects of intracerebral transfection of anti-RABV recombinant monoclonal nanobodies as antivirals against rabies in vivo, in a post-exposure protocol. Mice were intranasally inoculated with the RABV CVS strain and, 72 h later, were injected via the intracerebral route with two different anti-RABV llama-derived VHH nanobodies complexed with a transfection agent. One of the VHHs was able to reduce the viral load in mice, but no significant effect on survival was detected. Though not completely effective, nanobody therapy could be attempted in association with other antivirals to improve therapies against rabies.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 67, e63
Open AccessNanobodies as antivirals against rabies in experimentally infected mice
Despite its 100% lethality and approximately 59,000 human deaths every year, rabies still lacks an effective treatment. Numerous trials have aimed to impair the life cycle of Lyssavirus rabies (RABV), the primary worldwide lyssavirus causing rabies, but with limited success. Treatments targeting host factors and attempting to mitigate the damage caused by RABV have also been unsatisfactory. This article describes the effects of intracerebral transfection of anti-RABV recombinant monoclonal nanobodies as antivirals against rabies in vivo, in a post-exposure protocol. Mice were intranasally inoculated with the RABV CVS strain and, 72 h later, were injected via the intracerebral route with two different anti-RABV llama-derived VHH nanobodies complexed with a transfection agent. One of the VHHs was able to reduce the viral load in mice, but no significant effect on survival was detected. Though not completely effective, nanobody therapy could be attempted in association with other antivirals to improve therapies against rabies.
- 1 December 2017
- Published by Elsevier in Journal of Equine Veterinary Science
- Vol. 59, 64-70
Molecular Characterization of Equine Rotavirus Group A Detected in Argentinean Foals During 2009–2014
- 1 December 2017
- Published by Elsevier in Journal of Equine Veterinary Science
- Vol. 59, 64-70
Molecular Characterization of Equine Rotavirus Group A Detected in Argentinean Foals During 2009–2014